|
Pomalidomide (POM) + low-dose dexamethasone (LoDEX) after lenalidomide (LEN)-based second-line (2L) treatment (Tx) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): Analysis of progression-free survival (PFS) by level of disease control. |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Takeda |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Takeda |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Takeda |
|
|
|
Consulting or Advisory Role - Celgene |
Speakers' Bureau - Celgene |
Research Funding - Celgene |
|
|
Honoraria - Amgen; Celgene; Janssen |
Consulting or Advisory Role - Amgen; Celgene |
Research Funding - Janssen |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Janssen |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Signal Genetics |
Research Funding - Celgene; Novartis; Takeda |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Celgene; Janssen; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Janssen; Takeda |
Speakers' Bureau - Amgen; Celgene; Janssen |
Research Funding - Celgene; Janssen |
Expert Testimony - Janssen |
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen; Takeda |